Stay updated on Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Sign up to get notified when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.

Latest updates to the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedPublications note updated to say PubMed publications are automatically filled from PubMed, and the revision tag changed from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check27 days agoChange DetectedThe page no longer displays the government-funding operating-status notice; core study information such as the title, eligibility, and locations remains unchanged.SummaryDifference0.1%

- Check49 days agoChange DetectedNo significant changes detected in the Study Details for NCT04778397; core information such as the study design, eligibility criteria, and primary outcomes remains unchanged.SummaryDifference0.2%

- Check70 days agoChange DetectedAdditions introduce a current operating-status notice and a version upgrade (v3.2.0); deletions remove the previous version tag (v3.1.0). The page now communicates potential delays due to funding and points to official sources for updates.SummaryDifference2%

- Check77 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.0%

- Check92 days agoChange DetectedThe page revision updates from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.1%

Stay in the know with updates to Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.